(CLX) The Clorox - Ratings and Ratios
Disinfectants, Bleach, Litter, Dressings, Filtration
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.56% |
| Yield on Cost 5y | 2.84% |
| Yield CAGR 5y | 2.76% |
| Payout Consistency | 72.3% |
| Payout Ratio | 73.3% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 22.3% |
| Value at Risk 5%th | 36.2% |
| Relative Tail Risk | -1.38% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.84 |
| Alpha | -39.48 |
| CAGR/Max DD | -0.19 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.409 |
| Beta | 0.226 |
| Beta Downside | 0.208 |
| Drawdowns 3y | |
|---|---|
| Max DD | 39.83% |
| Mean DD | 14.04% |
| Median DD | 13.07% |
Description: CLX The Clorox October 30, 2025
The Clorox Company (NYSE: CLX) manufactures and markets a broad portfolio of consumer and professional products across four segments: Health & Wellness (cleaning, disinfecting, bleach, and professional food-service items), Household (cat litter, Glad bags, Kingsford grilling supplies), Lifestyle (Hidden Valley dressings, Brita water-filtration, Burt’s Bees personal-care) and International (a mix of the same brands plus vitamins and supplements). Its products reach shoppers via mass retailers, grocery chains, warehouse clubs, dollar stores, hardware outlets, drug and pet stores, military channels, third-party and owned e-commerce sites, and a direct sales force.
In FY 2023 Clorox generated roughly $7.8 billion in net sales, with an operating margin of about 15 % and a dividend yield near 2.5 %. The Health & Wellness segment contributed the largest share of revenue, driven by sustained demand for disinfecting solutions post-COVID-19, while the Lifestyle segment showed double-digit growth from premium-priced natural personal-care and water-filtration products.
Key economic drivers for CLX include inflationary pressure on raw-material costs (e.g., sodium hypochlorite and plastics), modest pricing power in the defensive household-products sector, and a consumer shift toward sustainable and “green” brands-trends that have historically supported modest revenue resilience. For a deeper quantitative assessment, you may find the ValueRay platform’s sector-adjusted valuation models useful.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (791.0m TTM) > 0 and > 6% of Revenue (6% = 406.3m TTM) |
| FCFTA 0.12 (>2.0%) and ΔFCFTA -0.67pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -7.96% (prev -0.04%; Δ -7.92pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.15 (>3.0%) and CFO 853.0m > Net Income 791.0m (YES >=105%, WARN >=100%) |
| Net Debt (2.91b) to EBITDA (1.45b) ratio: 2.01 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.76 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (123.0m) change vs 12m ago -1.33% (target <= -2.0% for YES) |
| Gross Margin 44.34% (prev 44.42%; Δ -0.09pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 122.8% (prev 135.9%; Δ -13.04pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 11.90 (EBITDA TTM 1.45b / Interest Expense TTM 93.0m) >= 6 (WARN >= 3) |
Altman Z'' 0.86
| (A) -0.10 = (Total Current Assets 1.70b - Total Current Liabilities 2.23b) / Total Assets 5.53b |
| (B) 0.04 = Retained Earnings (Balance) 200.0m / Total Assets 5.53b |
| (C) 0.20 = EBIT TTM 1.11b / Avg Total Assets 5.51b |
| (D) 0.03 = Book Value of Equity 166.0m / Total Liabilities 5.39b |
| Total Rating: 0.86 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 68.63
| 1. Piotroski 5.50pt |
| 2. FCF Yield 4.20% |
| 3. FCF Margin 9.39% |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda 2.01 |
| 6. ROIC - WACC (= 26.16)% |
| 7. RoE data missing |
| 8. Rev. Trend -14.57% |
| 9. EPS Trend 45.90% |
What is the price of CLX shares?
Over the past week, the price has changed by +3.87%, over one month by -6.32%, over three months by -7.52% and over the past year by -33.01%.
Is CLX a buy, sell or hold?
- Strong Buy: 2
- Buy: 2
- Hold: 13
- Sell: 3
- Strong Sell: 1
What are the forecasts/targets for the CLX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 124.6 | 15.4% |
| Analysts Target Price | 124.6 | 15.4% |
| ValueRay Target Price | 103.6 | -4% |
CLX Fundamental Data Overview November 20, 2025
P/E Trailing = 15.7206
P/E Forward = 16.5017
P/S = 1.804
P/B = 46.5805
P/EG = 2.8973
Beta = 0.565
Revenue TTM = 6.77b USD
EBIT TTM = 1.11b USD
EBITDA TTM = 1.45b USD
Long Term Debt = 2.48b USD (from longTermDebt, last quarter)
Short Term Debt = 307.0m USD (from shortTermDebt, last quarter)
Debt = 3.08b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.91b USD (from netDebt column, last quarter)
Enterprise Value = 15.13b USD (12.22b + Debt 3.08b - CCE 166.0m)
Interest Coverage Ratio = 11.90 (Ebit TTM 1.11b / Interest Expense TTM 93.0m)
FCF Yield = 4.20% (FCF TTM 636.0m / Enterprise Value 15.13b)
FCF Margin = 9.39% (FCF TTM 636.0m / Revenue TTM 6.77b)
Net Margin = 11.68% (Net Income TTM 791.0m / Revenue TTM 6.77b)
Gross Margin = 44.34% ((Revenue TTM 6.77b - Cost of Revenue TTM 3.77b) / Revenue TTM)
Gross Margin QoQ = 41.71% (prev 46.48%)
Tobins Q-Ratio = 2.74 (Enterprise Value 15.13b / Total Assets 5.53b)
Interest Expense / Debt = 0.84% (Interest Expense 26.0m / Debt 3.08b)
Taxrate = 23.36% (25.0m / 107.0m)
NOPAT = 848.4m (EBIT 1.11b * (1 - 23.36%))
Current Ratio = 0.76 (Total Current Assets 1.70b / Total Current Liabilities 2.23b)
Debt / Equity = -139.9 (out of range, set to none) (Debt 3.08b / totalStockholderEquity, last quarter -22.0m)
Debt / EBITDA = 2.01 (Net Debt 2.91b / EBITDA 1.45b)
Debt / FCF = 4.58 (Net Debt 2.91b / FCF TTM 636.0m)
Total Stockholder Equity = 71.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 14.31% (Net Income 791.0m / Total Assets 5.53b)
RoE = 1110 % (out of range, set to none) (Net Income TTM 791.0m / Total Stockholder Equity 71.2m)
RoCE = 43.31% (EBIT 1.11b / Capital Employed (Equity 71.2m + L.T.Debt 2.48b))
RoIC = 31.76% (NOPAT 848.4m / Invested Capital 2.67b)
WACC = 5.60% (E(12.22b)/V(15.29b) * Re(6.85%) + D(3.08b)/V(15.29b) * Rd(0.84%) * (1-Tc(0.23)))
Discount Rate = 6.85% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.64%
[DCF Debug] Terminal Value 79.37% ; FCFE base≈649.2m ; Y1≈701.2m ; Y5≈867.8m
Fair Price DCF = 124.1 (DCF Value 15.14b / Shares Outstanding 122.0m; 5y FCF grow 9.04% → 3.0% )
EPS Correlation: 45.90 | EPS CAGR: 6.98% | SUE: 0.20 | # QB: 0
Revenue Correlation: -14.57 | Revenue CAGR: -4.39% | SUE: 0.35 | # QB: 0
Additional Sources for CLX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle